Vascular Malformation Clinical Trials in San Francisco, California
2 recruitingSan Francisco, California
Showing 1–2 of 2 trials
Recruiting
Phase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
PIK3CA MutationVascular MalformationsPIK3CA-Related Overgrowth Spectrum (PROS)+4 more
Relay Therapeutics, Inc.277 enrolled31 locationsNCT06789913
Recruiting
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Gastrointestinal BleedingTelangiectasiaArteriovenous Malformations+4 more
Cure HHT10,000 enrolled16 locationsNCT06259292